Daily Brief Health Care: Celltrion Inc, Telix Pharmaceuticals, Akeso Biopharma Inc and more

In today’s briefing:

FnGuide Top 5 Plus Index Rebalance Preview: Celltrion Could Replace KT&G
Telix Pharmaceutical US ADS – Past Deal Record Hasn’t Been Strong, but Fortune Could Be Turning
Akeso Biopharma (9926.HK) – It’s Not Game over Yet

FnGuide Top 5 Plus Index Rebalance Preview: Celltrion Could Replace KT&G

The Samsung KODEX Top5Plus Total Return ETF (315930 KS) tracks the FnGuide Top 5 Plus Index and has an AUM of KRW 1,357bn (~US$1bn).
We currently see a high probability of Celltrion Inc (068270 KS) replacing KT&G Corporation (033780 KS) in the index at the June rebalance.
There is between 1-2 days of ADV to trade on the potential add and delete and smaller flows on the other index members due to capping and funding changes.

Telix Pharmaceuticals (TLX AU) aims to raise at least US$100m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
TLX is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
In this note, we talk about the deal dynamics and the listing impact.

We saw the collapse of Akeso’s share price after the Company released the clinical data of AK112 on ASCO. Judging from the market reaction, there are indeed“something unsatisfactory” about AK112.
Akeso’s high valuation mainly comes from the expectation that it would be a player that can compete on international stage. But investors’ confidence in AK112’s future commercialization has been shaken.
We advise investors to remain patient and “let the bullets fly”. It’s not yet time for the final result.But, if you want to bet, you need to pay the price.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network